Devising of Lazūq (A Conventional Unani Dosage Form) with reference to Transdermal Patch; Then and Now: A Critical Review

  • Dr Amreen Post-Graduate Research Scholar, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.
  • Asif Iqbal Siddiqui Associate Professor, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.
  • Mohd Nauman Saleem Assistant Professor & Head of Department, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.

Abstract

Objective: The endeavor is made to criticize the classical indications, preparations and application of Lazūq even after passing many centuries since its inception. Background: According to classical Unani literature, Lazūq is primarily formulated for headache, migraine, toothache, cervical pain, dropping of uvula and different types of pain like sciatica, backache, myalgia and some orthopedic conditions. Its approach is still conventional that encompasses thick sticky stuff of drug/s which is pasted over a cloth or thick paper, consequently, maximum ratio of medicinal properties remains insignificant owed to stratum corneum (layer of skin that functions as a barrier). Devising and method of drug delivery in classical form of Lazūq makes it inconvenient to the patient, thus, it drops patient’s compliance and anticipated efficacy. In this day and age, Unani practitioners do not prescribe it very often because of its devising and limited indications documented in classical literature. Hence, it’s now becoming out of practice. Whereas, modern medicine is practicing its novel approach epitomized as Transdermal patch for several bodily conditions like Acute post-operative pain, Alzheimer disease, Angina pectoris, Anti-emetic patch, Atrial fibrillation, Attention deficit hyperactivity disorder, Dementia, Depression, Dysmenorrhea, Hypertension, Local dermal analgesia, Menopausal symptoms, Motion sickness, Osteoporosis, Overactive bladder, Parkinson’s disease, Post herpetic neuralgia pain, Smoking cessation, Tic disorder, Tourette syndrome and to prevent pregnancy. In transdermal patch, drug is used in micro/nano form with chemically produced permeation enhancers (CPEs) and other smart physio-chemical techniques that makes it very easy to apply, imparts maximum active pharmaceutical ingredients with controlled release of drug. Methodology: Ancient classical Unani formulations of Lazūq was appraised and then its course with respect to today’s newer formulations as transdermal patch was reviewed to look for its progress and application in novel dosage form with the advantage of innovations in pharmaceutical and allied sciences. Conclusion: Classical Unani formulations of Lazūq must be reviewed, transformed, evaluated, coped and applied as per the standard operating procedures (SOPs) of transdermal drug delivery system. Future Prospects: New formulations of Lazūq should be designed and appraised from the medicinal treasure of Unani system of medicine for different therapeutic conditions.


 

Keywords: Unani, Ilmul Saidla, Lazooq, Lasooq, Formulation of Lazūq, Formulation of Transdermal Patch, Transdermal Drug Delivery System

Downloads

Download data is not yet available.

Author Biographies

Dr Amreen, Post-Graduate Research Scholar, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.

Post-Graduate Research Scholar, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.

Asif Iqbal Siddiqui, Associate Professor, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.

Associate Professor, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.

Mohd Nauman Saleem, Assistant Professor & Head of Department, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.

Assistant Professor & Head of Department, Post-Graduate Department of Ilmul Saidla, Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi, University of Delhi, India.

References

1. WHO international standard terminologies on Unani medicine, (2022), Published by WHO, Geneva: World Health Organization, License: CC BY-NC-SA 3.0 IGO., Pp: 382.
2. Ansari., et al., (2016), Modification in Unani drug dosage forms-Need of the hour, Published by International Journal of Advances in Pharmacy Medicine and Bioallied Sciences, Volume-4, Issue-1, Pp: 22-28.
3. Hamdani, S. K. H., (2010), 4th Edition, Usule Tib, print at: Silasar imaging system offset printers, New Delhi, Published by NCPUL, New Delhi, Pp: 361.
4. Wadud A. (2004), Ashrah al-Advia (Kulliyat-e-Advia). Burhan Pur: Printed by Mumtaz Screen Printer; 2004. Pp: 54-69.
5. Kabir, H., (2002), Introduction to Ilmul Advia, 1st Edition, published by Shamsher Publisher and Distributors, Aligarh, UP, India, printed at Bharat offset, Delhi, India, Pp: 107.
6. Amreen., et al, Concept of Lazūq (A Classical Unani Dosage Form) and its Evolution as Transdermal Patch (A Novel Drug Delivery System): An Analyzation, published by European Journal of Pharmaceutical and Medical Research, EJPMR, 2024, 11(4), Pp: 65-75.
7. Wong WF, Ang KP, Sethi G, Looi CY. Recent Advancement of Medical Patch for Transdermal Drug Delivery. Medicina (Kaunas). 2023 Apr 17;59(4):778. https://doi.org/10.3390/medicina59040778 PMid:37109736 PMCid:PMC10142343
8. Phatale V, Vaiphei KK, Jha S, Patil D, Agrawal M, Alexander A. Overcoming skin barriers through advanced transdermal drug delivery approaches. J Control Release. 2022 Nov; 351:361-380. https://doi.org/10.1016/j.jconrel.2022.09.025 PMid:36169040
9. Kramer SN. The Sumerians: Their History, Culture, and Character. Chicago and London: The University of Chicago Press; 1963.
10. Magner LN. A History of Medicine. 2nd edition. Boca Raton, FL: Taylor & Francis Group; 2005.
11. Geller MJ. Ancient Babylonian Medicine. 1st edition. Malden, MA: Wiley-Blackwell; 2010. https://doi.org/10.1002/9781444319996
12. Qadeer, A., (2024), History of Medicine and Medical Ethics, 8th edition, Published by publication division, Aligarh Muslim University, Aligarh, India, Pp: 41-43.
13. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. Br J Pharmacol. 2015 May;172(9):2179-209. https://doi.org/10.1111/bph.13059 PMid:25560046 PMCid:PMC4403087
14. Ebbell B. The Papyrus Ebers: The Greatest Egyptian Medical Document. Copenhagen: Levin & Munksgaard; 1937.
15. La Wall CH. Four Thousand Years of Pharmacy: An Outline History of Pharmacy and the Allied Sciences. Philadelphia, PA and London: JB Lippincott Co; 1927.
16. Chien Y.W. Development of transdermal drug delivery systems. Drug Dev Ind Pharm. 1987; 13:589-651. https://doi.org/10.3109/03639048709105212
17. Ewing, S. (1999). Black mustard (Brassica nigra). Ethnobotanical Leaflets, 1999(1), 8.
18. Bender GA, Thom RA. Great Moments in Medicine and Pharmacy: A History of Medicine and Pharmacy in Pictures. Detroit, MI: Northwood Institute Press; 1966.
19. B. C. Finnin and T. M. Morgan, "Transdermal penetration enhancers: applications, limitations, and potential," Journal of Pharmaceutical Sciences, 1999;88(10):955-958. https://doi.org/10.1021/js990154g PMid:10514338
20. L. D. Kronenberg, The Ultimate Text in Constitutional Hydrotherapy, 2012.
21. Ritter, T. J., Mother's Remedies: Over One Thousand Tried and Tested Remedies from Mothers of the United States and Canada, Old Time Remedies, 2008.
22. Sina, I., (YNM), Al-Qanun fil-Tibb, (Urdu translated by Ghulam Hasnain Kantoori), Printed at H. S. offset press, Published by Idara Kitab-us-Shifa, New Delhi. Volume-3, part-2, Pp: 1131.
23. Ghani, N., (2010), Qarabadeen-e-Najam-ul-Ghani. New Delhi: Central Council for Research in Unani medicine. Pp: 879-880.
24. Kabeeruddin. (2006), Al-Qarabadeen. 2nd Edition. CCRUM, Dept. of AYUSH, Ministry of Health and Family Welfare, Govt, of India; New Delhi: 2006. Pp. 991-992.
25. Khan A. (2005), Qarabadeen-e-Azam va Akmal. (Urdu translation by CCRUM), Dept. of AYUSH, Ministry of Health and Family Welfare, Govt. of India, New Delhi, 2005. Pp: 437-438.
26. Mishra S, Verma P, Gupta SK, Pandey S, Ojha S, Nanocarrier and Herbal Based Transdermal Patch: An Advantage Over Other Drug Delivery Systems, Annals Ayurvedic Med. 2022;11(2) 145-156, https://doi.org/10.5455/AAM.11486
27. Rajput, S.P., et al, Formulation and Evaluation of Herbal Transdermal Patches in Treatment of Wound Healing, Published by international Journal of Scientific Development and Research, 2022;7(7):675-701.
28. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008 Nov;26(11):1261-8. https://doi.org/10.1038/nbt.1504 PMid:18997767 PMCid:PMC2700785
29. Mohammed YH, Moghimi HR, Yousef SA, Chandrasekaran NC, Bibi CR, Sukumar SC, Grice JE, Sakran W, Roberts MS. Efficacy, safety and targets in topical and transdermal active and excipient delivery. Percutaneous Penetration Enhancers Drug Penetration into/through the Skin: Methodology and General Considerations. 2017:369-91. https://doi.org/10.1007/978-3-662-53270-6_23 PMCid:PMC7121119
30. Mishra A, Pathak AK. Plasticizers: A vital excipient in novel pharmaceutical formulations. Current Research in Pharmaceutical Sciences. 2017 May 8:1-0. https://doi.org/10.24092/CRPS.2017.070101
31. Defraeye T, Bahrami F, Rossi RM. Inverse Mechanistic Modeling of Transdermal Drug Delivery for Fast Identification of Optimal Model Parameters. Front Pharmacol. 2021 Apr 29; 12:641111. https://doi.org/10.3389/fphar.2021.641111 PMid:33995047 PMCid:PMC8117338
32. Kovacik A, Kopecna M, Vavrova K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Expert Opin Drug Deliv. 2020 Feb;17(2):145-155. doi: 10.1080/17425247.2020.1713087. Epub 2020 Jan 14. https://doi.org/10.1080/17425247.2020.1713087 PMid:31910342
33. Amreen., et al, Design, development and evaluation of classical Unani dosage form and drug delivery system with respect to novel dosage form: A review. International Journal of Unani and Integrative Medicine. 2024:8(1), Pp: 16-22. https://doi.org/10.33545/2616454X.2024.v8.i1a.256
34. Sarangi et al, Novel Herbal Drug Delivery System An Overview, Archives of Medicine and Health Sciences. 2018;6(1):171-179. https://doi.org/10.4103/amhs.amhs_88_17
35. Laffleur, F., et al, (2020), Advances in drug delivery systems: Work in progress still needed? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305387/ . https://doi.org/10.1016/j.ijpharm.2020.119912 PMid:32971178
36. Benson HA. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005 Jan;2(1):23-33. https://doi.org/10.2174/1567201052772915 PMid:16305405
37. Jasti BR, Abraham W, Ghosh TK. Transdermal and Topical drug delivery systems. In Theory and practice of contemporary pharmaceutics 2021 Feb 25 (Pp. 423-454). CRC Press. https://doi.org/10.1201/9780203644478-18
38. Ramadon D, McCrudden MTC, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Deliv Transl Res. 2022 Apr;12(4):758-791. https://doi.org/10.1007/s13346-021-00909-6 PMid:33474709 PMCid:PMC7817074
39. Ning X, Wiraja C, Chew WTS, Fan C, Xu C. Transdermal delivery of Chinese herbal medicine extract using dissolvable microneedles for hypertrophic scar treatment. Acta Pharm Sin B. 2021 Sep;11(9):2937-2944. https://doi.org/10.1016/j.apsb.2021.03.016 PMid:34589406 PMCid:PMC8463281
40. Sabir F, Qindeel M, Rehman AU, Ahmad NM, Khan GM, Csoka I, Ahmed N. An efficient approach for development and optimisation of curcumin-loaded solid lipid nanoparticles' patch for transdermal delivery. J Microencapsul. 2021 Jun;38(4):233-248. https://doi.org/10.1080/02652048.2021.1899321 PMid:33689550
41. Mishra SU, Bishnoi RS, Maurya RA, Jain DE. Boswellia Serrata ROXB. A Bioactive Herb with Various Pharmacological Activities. Asian J. Pharm. Clin. Res. 2020 Nov 7;13(11):33-9. https://doi.org/10.22159/ajpcr.2020.v13i11.39354
42. Otterbach A, Lamprecht A. Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches. Pharmaceutics. 2021 Mar 1;13(3):320. https://doi.org/10.3390/pharmaceutics13030320 PMid:33804395 PMCid:PMC7999216
43. Johnson P, Hansen D, Matarazzo D, Petterson L, Swisher C, Trappolini A. Transderm Scop patches for prevention of motion sickness. N Engl J Med. 1984 Aug 16;311(7):468-9. https://doi.org/10.1056/NEJM198408163110713 PMid:6749195
44. Swaminathan SK, Strasinger C, Kelchen M, Carr J, Ye W, Wokovich A, Ghosh P, Rajagopal S, Ueda K, Fisher J, Kandimalla KK, Brogden NK. Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. AAPS PharmSciTech. 2020 Apr 16;21(3):117. https://doi.org/10.1208/s12249-020-01658-4 PMid:32300962
45. Dahlstrom CG, Rasmussen K, Bagger JP, Henningsen P, Haghfelt T. Transdermal nitroglycerin (Transiderm-Nitro) in the treatment of unstable angina pectoris. Dan Med Bull. 1986 Oct;33(5):265-7. PMID: 3096643.
46. Greco R, D'Alterio D, Schiattarella M, Boccia A, Greco L, Marsico F. Efficacy of a new transdermal nitroglycerin patch (Deponit 10) for stable angina pectoris. Am J Cardiol. 1988 Mar 25;61(9):44E-51E. https://doi.org/10.1016/0002-9149(88)90090-2 PMid:3126635
47. Mammen MV, Tripathi M, Chandola HC, Tyagi A, Bais PS, Sanjeev OP. Comparison of Enhancement of Analgesic Effect of Intrathecal Neostigmine by Intrathecal Clonidine and Transdermal Nitroglycerin Patch on Bupivacaine Spinal Anesthesia. Anesth Essays Res. 2017 Oct-Dec;11(4):993-997. https://doi.org/10.4103/aer.AER_68_17 PMid:29284862 PMCid:PMC5735501
48. Savonitto S, Motolese M, Agabiti-Rosei E. Antianginal effect of transdermal nitroglycerin and oral nitrates given for 24 hours a day in 2,456 patients with stable angina pectoris. The Italian Multicenter Study. Int J Clin Pharmacol Ther. 1995 Apr;33(4):194-203. PMID: 7620688.
49. Guo JM, Shi XX, Yang SW, Qian QF, Huang Y, Xie YQ, Ou P. [Efficacy of clonidine transdermal patch in treatment of moderate to severe tic disorders in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2017 Jul;19(7):786-789. Chinese. doi: https://doi.org/10.7499/j.issn.1008-8830.2017.07.011 . PMID: 28697832; PMCID: PMC7389911.
50. Kang H, Zhang YF, Jiao FY, Guo XY, Gao XM. [Efficacy of clonidine transdermal patch for treatment of Tourette's syndrome in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2009 Jul;11(7):537-9. Chinese. PMID: 19650984.
51. Ke GM, Wang L, Xue HY, Lu WL, Zhang X, Zhang Q, Guo HY. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. Biol Pharm Bull. 2005 Feb;28(2):305-10. https://doi.org/10.1248/bpb.28.305 PMid:15684489
52. Song PP, Jiang L, Li XJ, Hong SQ, Li SZ, Hu Y. The Efficacy and Tolerability of the Clonidine Transdermal Patch in the Treatment for Children with Tic Disorders: A Prospective, Open, Single-Group, Self-Controlled Study. Front Neurol. 2017 Feb 23; 8:32. PMID: 28280480; PMCID: PMC5322220. https://doi.org/10.3389/fneur.2017.00032
53. Antihypertensive Patch Italian Study (APIS) Investigators. One-year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension-a multicentre open label study: The Antihypertensive Patch Italian Study (APIS) Investigators. Clinical Autonomic Research. 1993 Dec;3(6):379-83. https://doi.org/10.1007/BF01829457
54. Youngkin EQ. Estrogen replacement therapy and the estraderm transdermal system. Nurse Pract. 1990 May;15(5):19-26, 31. https://doi.org/10.1097/00006205-199005000-00005 PMid:2342664
55. Baumrucker SJ. Duragesic (transdermal fentanyl) in hospice care. Am J Hosp Palliat Care. 1996 Nov-Dec;13(6):13-5. https://doi.org/10.1177/104990919601300608 PMid:8945097
56. Chen HK, Lan TH, Wu BJ. A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2013 Feb;263(1):75-82. https://doi.org/10.1007/s00406-012-0338-3 PMid:22729212
57. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. J Formos Med Assoc. 1998 Aug;97(8):547-51. PMID: 9747065.
58. Rich JD. Transdermal nicotine patch for smoking cessation. N Engl J Med. 1992 Jan 30;326(5):344-5. PMID: 1728743. https://doi.org/10.1056/NEJM199201303260512
59. Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, Shen R, Arver S, Beall G. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998 Sep;83(9):3155-62. https://doi.org/10.1210/jcem.83.9.5079 PMid:9745419
60. De Sanctis V, Vullo C, Urso L, Rigolin F, Cavallini A, Caramelli K, Daugherty C, Mazer N. Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:891-900. PMID: 10091163.
61. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol. 1999 Oct;94(4):498-503. https://doi.org/10.1016/S0029-7844(99)00359-2 PMid:10511348
62. Buch A, Shen L, Kelly S, Sahota R, Brezovic C, Bixler C, Powell J. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara. Menopause. 1998 Summer;5(2):107-12. https://doi.org/10.1097/00042192-199822010-00009 PMid:9689205
63. Rozenbaum H, Birkhauser M, De Nooyer C, Lambotte R, Pornel B, Schneider H, Studd J. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy. Maturitas. 1996 Nov;25(3):161-73. https://doi.org/10.1016/S0378-5122(96)01068-7 PMid:8981333
64. Desai MJ, Siriki R, Wang D. Treatment of pain in Dercum's disease with Lidoderm (lidocaine 5% patch): a case report. Pain Med. 2008 Nov;9(8):1224-6. https://doi.org/10.1111/j.1526-4637.2008.00417.x PMid:18346067
65. Karmarkar A, Lieberman I. Management of complex regional pain syndrome type II using lidoderm 5% patches. Br J Anaesth. 2007 Feb;98(2):261-2. https://doi.org/10.1093/bja/ael343 PMid:17251215
66. Zieman M. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra). Fertil Steril. 2002 Feb;77(2 Suppl 2): S1-2. https://doi.org/10.1016/S0015-0282(01)03274-5 PMid:11849629
67. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002 Feb;77(2 Suppl 2):S13-8. https://doi.org/10.1016/S0015-0282(01)03275-7 PMid:11849631
68. Badoi D, Crauciuc E, Rusu L, Luca V. Therapy with climara in surgical menopause. Rev Med Chir Soc Med Nat Iasi. 2012 Jul-Sep;116(3):828-33. PMID: 23272537.
69. Taggart W, Dandekar K, Ellman H, Notelovitz M. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara). Menopause. 2000 Sep-Oct;7(5):364-9. https://doi.org/10.1097/00042192-200007050-00010 PMid:10993035
70. Dull P. Transdermal oxybutynin (oxytrol) for urinary incontinence. Am Fam Physician. 2004 Dec 15;70(12):2351-2. PMID: 15617300.
71. Ho C. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder. Issues Emerg Health Technol. 2001 Oct;(24):1-4. PMID: 11776281.
72. Wokovich AM, Shen M, Doub WH, Machado SG, Buhse LF. Evaluating elevated release liner adhesion of a transdermal drug delivery system (TDDS): a study of Daytrana™ methylphenidate transdermal system. Drug Dev Ind Pharm. 2011 Oct;37(10):1217-24. https://doi.org/10.3109/03639045.2011.565773 PMid:21438703
73. Jessen L, Kovalick LJ, Azzaro AJ. The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder. P T. 2008 Apr;33(4):212-46. PMID: 19750165; PMCID: PMC2730099.
74. Kurz A, Farlow M, Lefevre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. International journal of clinical practice. 2009 May;63(5):799-805. https://doi.org/10.1111/j.1742-1241.2009.02052.x PMid:19392927 PMCid:PMC2734925
75. Lefevre G, Pommier F, Sedek G, Allison M, Huang HL, Kiese B, Ho YY, Appel-Dingemanse S. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol. 2008 Feb;48(2):246-52. https://doi.org/10.1177/0091270007312154 PMid:18199897
76. Chatsis V. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease. Issues Emerg Health Technol. 2008 Feb;(112):1-6. PMID: 18354859.
77. Abramowicz M, Zuccotti G, Pflomm JM, Daron SM, Houst BM, Zanone CE, Dalton VK, Epstein EJ, Hirsch J, Juurlink DN, Kim RB. A granisetron patch (Sancuso). Medical Letter on Drugs and Therapeutics. 2008 Dec 15;50(1301-1302):103-4.
78. Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. 2009 Dec;15(4):223-31. https://doi.org/10.1177/1078155209104063 PMid:19304880
79. Le TN, Adler MT, Ouillette H, Berens P, Smith JA. Observational Case Series Evaluation of the Granisetron Transdermal Patch System (Sancuso) for the Management of Nausea/Vomiting of Pregnancy. Am J Perinatol. 2017 Jul;34(9):851-855. doi: 10.1055/s-0037-1598652. https://doi.org/10.1055/s-0037-1598652 PMid:28231602
80. Yamashita T, Ikeda T, Akita Y. Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). J Cardiol. 2019 May;73(5):386-393. https://doi.org/10.1016/j.jjcc.2018.11.009 PMid:30591320
81. Transdermal buprenorphine (Butrans) for chronic pain. Med Lett Drugs Ther. 2011 Apr 18;53(1362):31-2. PMID: 21502936.
82. James IG, O'Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manage. 2010 Aug;40(2):266-78. https://doi.org/10.1016/j.jpainsymman.2010.01.013 PMid:20541900
83. Smyth M, Haupt TS, Gregoire MC. Retrospective Review of the Use of Transdermal Buprenorphine Patches (Butrans) in a Pediatric Population. J Palliat Med. 2020 Aug;23(8):1094-1097. https://doi.org/10.1089/jpm.2019.0381 PMid:31770045
84. Musselman M, Faden J, Citrome L. Asenapine: an atypical antipsychotic with atypical formulations. Ther Adv Psychopharmacol. 2021 Sep 11; 11:20451253211035269. https://doi.org/10.1177/20451253211035269 PMid:34540197 PMCid:PMC8442490
85. Suzuki K, Castelli M, Komaroff M, Starling B, Terahara T, Citrome L. Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070). J Clin Psychopharmacol. 2021 May-Jun 01;41(3):286-294. https://doi.org/10.1097/JCP.0000000000001383 PMid:33734167 PMCid:PMC8083160
86. Cutler AJ, Suzuki K, Starling B, Balakrishnan K, Komaroff M, Castelli M, Meeves S, Childress AC. Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study. J Child Adolesc Psychopharmacol. 2022 Mar;32(2):89-97. https://doi.org/10.1089/cap.2021.0107 PMid:35020462 PMCid:PMC8972004
87. Kim YH, Choi HY, Lim HS, Lee SH, Jeon HS, Hong D, Kim SS, Choi YK, Bae KS. Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Des Devel Ther. 2015 Mar 10;9:1419-26. https://doi.org/10.2147/DDDT.S78555 PMid:25792802 PMCid:PMC4362658
88. Yoon SK, Bae KS, Hong DH, Kim SS, Choi YK, Lim HS. Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers. Drug Des Devel Ther. 2020 May 5;14:1729-1737. https://doi.org/10.2147/DDDT.S244957 PMid:32440098 PMCid:PMC7211298
89. Saleem, M.N., et al, Formulation Design and Development of an Unani Transdermal Patch for Antiemetic Therapy and Its Pharmaceutical Evaluation, Hindawi Publishing Corporation Scientifica, Volume 2016, Article ID 7602347, https://doi.org/10.1155/2016/7602347 PMid:27403377 PMCid:PMC4925991
90. Chinnasamy G, Chandrasekharan S, Koh TW, Bhatnagar S. Synthesis, Characterization, Antibacterial and Wound Healing Efficacy of Silver Nanoparticles From Azadirachta indica. Front Microbiol. 2021 Feb 19; 12:611560. https://doi.org/10.3389/fmicb.2021.611560 PMid:33679635 PMCid:PMC7932996
91. Sengsuk T, Songtipya P, Kalkornsurapranee E, Johns J, Songtipya L. Active Bio-Based Pressure-Sensitive Adhesive Based Natural Rubber for Food Antimicrobial Applications: Effect of Processing Parameters on Its Adhesion Properties. Polymers (Basel). 2021 Jan 7;13(2):199. https://doi.org/10.3390/polym13020199 PMid:33430498 PMCid:PMC7827535
92. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493-6. https://doi.org/10.1093/ajcp/45.4_ts.493 PMid:5325707
93. Diniz FR, Maia RCAP, Rannier L, Andrade LN, V Chaud M, da Silva CF, Corrêa CB, de Albuquerque Junior RLC, P da Costa L, Shin SR, Hassan S, Sanchez-Lopez E, Souto EB, Severino P. Silver Nanoparticles-Composing Alginate/Gelatine Hydrogel Improves Wound Healing In Vivo. Nanomaterials (Basel). 2020 Feb 23;10(2):390. https://doi.org/10.3390/nano12224071 PMid:36432393 PMCid:PMC9697418
94. Nematpour N, Farhadian N, Ebrahimi KS, Arkan E, Seyedi F, Khaledian S, Shahlaei M, Moradi S. Sustained release nanofibrous composite patch for transdermal antibiotic delivery. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2020 Feb 5; 586:124267. https://doi.org/10.1016/j.colsurfa.2019.124267
95. Akrami-Hasan-Kohal M, Tayebi L, Ghorbani M. Curcumin-loaded naturally-based nanofibers as active wound dressing mats: Morphology, drug release, cell proliferation, and cell adhesion studies. New Journal of Chemistry. 2020;44(25):10343-51. https://doi.org/10.1039/D0NJ01594F
96. Khan S, Sharman T. Transdermal Medications. [Updated 2023 Feb 6]. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556035/
97. Transdermal Patches, Developing A Transdermal Patch Through A CDMO, https://www.tapemark.com/transdermal-patches#:~:text=Transdermal%20patches%20are%20a%20method,skin%20and%20into%20the%20bloodstream .
Crossmark
Statistics
262 Views | 17 Downloads
How to Cite
1.
Amreen D, Siddiqui AI, Saleem MN. Devising of Lazūq (A Conventional Unani Dosage Form) with reference to Transdermal Patch; Then and Now: A Critical Review. JDDT [Internet]. 15Apr.2024 [cited 12Jul.2024];14(4):155-64. Available from: https://jddtonline.info/index.php/jddt/article/view/6511